Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Risk factors for the development of melanoma

Clara Curiel-Lewandrowski, MD
Section Editors
Michael B Atkins, MD
Hensin Tsao, MD, PhD
Deputy Editor
Rosamaria Corona, MD, DSc


Melanoma is the most serious form of skin cancer. The rapid increase in the incidence of melanoma and its associated mortality require a detailed understanding of the risk factors associated with melanoma.

Here we will review epidemiologic changes in the incidence and mortality, specific risk factors, and the management of patients at high risk for the development of melanoma. Primary prevention, screening, and techniques of skin examination are discussed separately. (See "Primary prevention of melanoma" and "Screening and early detection of melanoma in adults and adolescents" and "Melanoma: Clinical features and diagnosis".)


The incidence of melanoma is rising dramatically, and despite efforts at screening, mortality has not decreased appreciably. Understanding the epidemiology provides information about important causative factors.

Incidence — In the United States, melanoma is the fifth leading cancer in men and the sixth in women [1]. In 2011, the overall age-adjusted incidence of melanoma was 19.7 per 100,000 [2]. From 1982 to 2011, melanoma incidence rates doubled in the United States, while mortality rates remained constant [2]. The incidence rates increased with age and were highest among non-Hispanic whites (24.6 per 100,000). Among white individuals, the incidence rates of invasive melanoma were 27.4/100,000 men and 16.7/100,000 women per year in the years 2006 to 2010 [3]. Lentigo maligna melanoma has been increasing at a higher rate compared with other subtypes of melanoma combined for patients aged 45 and older [4]. However, the incidence of melanoma in the United States may be underestimated because many cases diagnosed and treated in private practices are not reported to cancer registries [5,6].

The incidence of melanoma is also rising worldwide. The estimated age-standardized incidence rates of melanoma in men and women worldwide increased from 2.3 and 2.2/100,000 people, respectively, in 1990 to 3.1 and 2.8/100,000 people in 2008 [7,8]. Between the early 1970s and 2000, the estimated incidence of melanoma in Central Europe increased from 3 to 4 cases/100,000 inhabitants per year to 10 to 15 cases/100,000 inhabitants per year [9]. In contrast to North America and Australia, European incidence rates of melanoma in females exceed those in men [10].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 07, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.
  2. Guy GP Jr, Thomas CC, Thompson T, et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep 2015; 64:591.
  3. www.seer.cancer.gov/statfacts/html/melan.html (Accessed on February 05, 2014).
  4. Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125:685.
  5. Cockburn M, Swetter SM, Peng D, et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 2008; 59:1081.
  6. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst 2009; 101:533.
  7. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893.
  8. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827.
  9. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3.
  10. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 Suppl 6:vi1.
  11. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331:481.
  12. Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch Dermatol 1996; 132:881.
  13. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666.
  14. Waldmann A, Nolte S, Weinstock MA, et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012; 106:970.
  15. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005; 23:4735.
  16. Lange JR, Palis BE, Chang DC, et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007; 25:1363.
  17. Jafarian F, Powell J, Kokta V, et al. Malignant melanoma in childhood and adolescence: report of 13 cases. J Am Acad Dermatol 2005; 53:816.
  18. Stanelle EJ, Busam KJ, Rich BS, et al. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis. J Pediatr Surg 2015; 50:1019.
  19. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006; 166:1907.
  20. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005; 141:477.
  21. Baade P, Coory M. Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Aust N Z J Public Health 2005; 29:383.
  22. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011; 65:S17.
  23. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011; 65:S78.
  24. Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66:201.
  25. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340:1341.
  26. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73:198.
  27. Bulliard JL, Cox B, Elwood JM. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control 1994; 5:234.
  28. Devesa SS, Grauman DJ, Blot WJ, et al. Atlas of cancer mortality in the United States 1950–1994, NIH Pub No. 99–4564, Bethesda, MD 1999.
  29. Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev 2000; 9:291.
  30. Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195.
  31. Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control 2007; 18:295.
  32. Buckel TB, Goldstein AM, Fraser MC, et al. Recent tanning bed use: a risk factor for melanoma. Arch Dermatol 2006; 142:485.
  33. Noonan FP, Zaidi MR, Wolnicka-Glubisz A, et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun 2012; 3:884.
  34. Premi S, Wallisch S, Mano CM, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science 2015; 347:842.
  35. Nelemans PJ, Groenendal H, Kiemeney LA, et al. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 1993; 101:252.
  36. Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure--the Western Canada Melanoma Study. Int J Cancer 1985; 35:427.
  37. Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer 2006; 94:743.
  38. Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24:3172.
  39. Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23:1080.
  40. Cooke KR, Fraser J. Migration and death from malignant melanoma. Int J Cancer 1985; 36:175.
  41. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73:75.
  42. Young AR. The sunburn cell. Photodermatol 1987; 4:127.
  43. Centers for Disease Control and Prevention (CDC). Use of indoor tanning devices by adults--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:323.
  44. Guy GP Jr, Berkowitz Z, Watson M, et al. Indoor tanning among young non-Hispanic white females. JAMA Intern Med 2013; 173:1920.
  45. Guy GP Jr, Berkowitz Z, Everett Jones S, et al. Prevalence of Indoor Tanning and Association With Sunburn Among Youth in the United States. JAMA Dermatol 2017; 153:387.
  46. El Ghissassi F, Baan R, Straif K, et al. A review of human carcinogens--part D: radiation. Lancet Oncol 2009; 10:751.
  47. Wehner MR, Chren MM, Nameth D, et al. International prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014; 150:390.
  48. International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.
  49. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014; 70:847.
  50. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345:e4757.
  51. Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:562.
  52. Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998; 38:89.
  53. Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 1990; 108:1274.
  54. Vajdic CM, Kricker A, Giblin M, et al. Artificial ultraviolet radiation and ocular melanoma in Australia. Int J Cancer 2004; 112:896.
  55. Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld N, et al. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology 2009; 116:340.
  56. Lazovich D, Isaksson Vogel R, Weinstock MA, et al. Association Between Indoor Tanning and Melanoma in Younger Men and Women. JAMA Dermatol 2016; 152:268.
  57. Schneider S, Krämer H. Who uses sunbeds? A systematic literature review of risk groups in developed countries. J Eur Acad Dermatol Venereol 2010; 24:639.
  58. Ezzedine K, Malvy D, Mauger E, et al. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults. J Eur Acad Dermatol Venereol 2008; 22:186.
  59. Miyamura Y, Coelho SG, Schlenz K, et al. The deceptive nature of UVA tanning versus the modest protective effects of UVB tanning on human skin. Pigment Cell Melanoma Res 2011; 24:136.
  60. Vogel RI, Ahmed RL, Nelson HH, et al. Exposure to indoor tanning without burning and melanoma risk by sunburn history. J Natl Cancer Inst 2014; 106:dju112.
  61. Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755.
  62. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040.
  63. Purdue MP, From L, Armstrong BK, et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:2015.
  64. Pampena R, Kyrgidis A, Lallas A, et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77:938.
  65. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806.
  66. Olsen CM, Zens MS, Stukel TA, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009; 124:937.
  67. Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005; 14:1241.
  68. Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009; 45:3054.
  69. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439.
  70. Veierød MB, Weiderpass E, Thörn M, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst 2003; 95:1530.
  71. Barnhill RL. Melanocytic proliferations with architectural disorder and cytologic atypia (melanocytic dysplasia and atypical nevi). In: Pathology of Melanocytic Nevi and Melanoma, Barnhill RL (Ed), Butterworth-Heinemann, Newton, MA 1995. p.169.
  72. Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.
  73. Tsao HK, Pehamberger H, Sober AJ. Precursor lesions and markers for increased risk of melanoma. In: Cutaneous Melanoma, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing Inc, St. Louis 1998. p.65.
  74. Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73:1605.
  75. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233.
  76. Ribero S, Zugna D, Osella-Abate S, et al. Prediction of high naevus count in a healthy U.K. population to estimate melanoma risk. Br J Dermatol 2016; 174:312.
  77. Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998; 77:843.
  78. Rivers JK. Is there more than one road to melanoma? Lancet 2004; 363:728.
  79. Vourc'h-Jourdain M, Martin L, Barbarot S, aRED. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68:493.
  80. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28.
  81. Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352.
  82. Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732.
  83. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349:2233.
  84. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010; 146:265.
  85. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639.
  86. Levi F, Randimbison L, Te VC, La Vecchia C. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005; 117:877.
  87. Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010; 62:757.
  88. Chen T, Fallah M, Försti A, et al. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas. JAMA Dermatol 2015; 151:607.
  89. Pomerantz H, Huang D, Weinstock MA. Risk of subsequent melanoma after melanoma in situ and invasive melanoma: a population-based study from 1973 to 2011. J Am Acad Dermatol 2015; 72:794.
  90. Greene MH. The genetics of hereditary melanoma and nevi. 1998 update. Cancer 1999; 86:2464.
  91. Fu T, Swetter SM, Tao L, et al. Characterizing subsequent primary melanomas (SPM) in adolescents and young adults: A population-based study from 1973 to 2011. J Am Acad Dermatol 2016; 74:181.
  92. Siskind V, Hughes MC, Palmer JM, et al. Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol 2011; 131:461.
  93. Baumert J, Schmidt M, Giehl KA, et al. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res 2009; 19:24.
  94. Rivers JK. Melanoma. Lancet 1996; 347:803.
  95. Carey WP Jr, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74:3118.
  96. Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994; 54:489.
  97. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.
  98. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970.
  99. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328.
  100. Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491:449.
  101. Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97:998.
  102. Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al. Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure. JAMA Dermatol 2016; 152:776.
  103. Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995; 75:707.
  104. Kahn HS, Tatham LM, Patel AV, et al. Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA 1998; 280:910.
  105. Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87:991.
  106. Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 2011; 147:790.
  107. Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104:1962.
  108. Ascha M, Ascha MS, Tanenbaum J, Bordeaux JS. Risk Factors for Melanoma in Renal Transplant Recipients. JAMA Dermatol 2017; 153:1130.
  109. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274.
  110. Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol 2015; 172:885.
  111. Ward EM, Burnett CA, Ruder A, Davis-King K. Industries and cancer. Cancer Causes Control 1997; 8:356.
  112. Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 2007; 137:2098.
  113. Asgari MM, Maruti SS, Kushi LH, White E. Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Arch Dermatol 2009; 145:879.
  114. Millen AE, Tucker MA, Hartge P, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042.
  115. Liu J, Shen B, Shi M, Cai J. Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study. PLoS One 2016; 11:e0147056.
  116. Wang J, Li X, Zhang D. Coffee consumption and the risk of cutaneous melanoma: a meta-analysis. Eur J Nutr 2016; 55:1317.
  117. Yew YW, Lai YC, Schwartz RA. Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies. Am J Clin Dermatol 2016; 17:113.
  118. Wu S, Han J, Song F, et al. Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma. Epidemiology 2015; 26:898.
  119. Conney AH, Lu YP, Lou YR, et al. Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis. Front Oncol 2013; 3:144.
  120. Ravi D, Muniyappa H, Das KC. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. Mol Cell Biochem 2008; 308:193.
  121. Caini S, Masala G, Saieva C, et al. Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2017; 140:2246.
  122. Wu S, Han J, Feskanich D, et al. Citrus Consumption and Risk of Cutaneous Malignant Melanoma. J Clin Oncol 2015; 33:2500.
  123. Sayre RM, Dowdy JC. The increase in melanoma: are dietary furocoumarins responsible? Med Hypotheses 2008; 70:855.
  124. Merimsky O, Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998; 16:585.
  125. Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25:309.
  126. Gandini S, Iodice S, Koomen E, et al. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011; 47:2607.
  127. Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011; 103:1469.
  128. Kvaskoff M, Mesrine S, Fournier A, et al. Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women. Arch Intern Med 2007; 167:2061.
  129. Somigliana E, Vigano' P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101:331.
  130. Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92:201.
  131. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006; 17:582.
  132. Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67:347.
  133. Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. J Neural Transm (Vienna) 2009; 116:1503.
  134. Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol 2014; 179:85.
  135. Dalvin LA, Damento GM, Yawn BP, et al. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc 2017; 92:1070.
  136. Zanetti R, Loria D, Rosso S. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 2006; 16:201.
  137. Olsen JH, Tangerud K, Wermuth L, et al. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007; 22:1252.
  138. Li WQ, Qureshi AA, Ma J, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol 2013; 31:4394.
  139. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma]. Hautarzt 2009; 60:655.
  140. Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009; 34:524.
  141. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56:S65.
  142. Manganoni AM, Zane C, Pavoni L, et al. Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. Dermatol Online J 2011; 17:12.
  143. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895.
  144. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014; 174:964.
  145. Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. JAMA 2015; 313:2449.
  146. Matthews A, Langan SM, Douglas IJ, et al. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. PLoS Med 2016; 13:e1002037.
  147. Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300.